Significant Survival Differences for Grade Group 4 and Grade Group 5 Prostate Cancer: Detailed Reporting of Pathohistology and Modern Diagnostic Algorithms Are Needed To Tailor Treatment

被引：0
|
作者：
Heidenreich, Axel [1 ,2 ]
机构：
[1] Univ Hosp Cologne, Dept Urol Uro Oncol Robot Assisted & Specialized U, Kerpener Str 62, D-50937 Cologne, Germany
[2] Med Univ Vienna, Dept Urol, Vienna, Austria
来源：
EUROPEAN UROLOGY ONCOLOGY | 2024年 / 7卷 / 02期
关键词：
D O I：
10.1016/j.euo.2023.11.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：211 / 212
页数：2
相关论文
共 21 条
  • [1] Significant prognostic difference between Grade Group 4 and 5 in the 2014 International Society of Urological Pathology Grading System for High Grade Prostate Cancer with Bone Metastasis
    Yamada, Yasutaka
    Sakamoto, Shinichi
    Shimazaki, Jun
    Sugiura, Masahiro
    Amiya, Yoshiyasu
    Sasaki, Makoto
    Shima, Takayuki
    Komiya, Akira
    Suzuki, Noriyuki
    Akakura, Koichiro
    Ichikawa, Tomohiko
    Nakatsu, Hiroomi
    PROSTATE INTERNATIONAL, 2017, 5 (04) : 143 - 148
  • [2] QUANTIFICATION OF PERINEURAL CANCER INVASION ON PROSTATE NEEDLE CORE BIOPSY IS USEFUL FOR RISK STRATIFICATION IN PATIENTS WITH GRADE GROUP 2 OR 3 CANCER, BUT NOT IN THOSE WITH GRADE GROUP 4-5 CANCER
    Teramoto, Yuki
    Wang, Ying
    Miyamoto, Hiroshi
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1195 - E1195
  • [3] Quantification of perineural cancer invasion on systematic needle core biopsy of the prostate is useful for risk stratification in patients with Grade Group 2 or 3 cancer, but not in those with Grade Group 4-5 cancer
    Teramoto, Y.
    Wang, Y.
    Miyamoto, H.
    EUROPEAN UROLOGY, 2024, 85 : S1080 - S1081
  • [4] MRI characteristics and oncological follow-up of patients with ISUP grade group 4 or 5 prostate cancer
    Boschheidgen, M.
    Schimmoeller, L.
    Kastl, R.
    Drewes, L. R.
    Jannusch, K.
    Radke, K. L.
    Kirchner, J.
    Ullrich, T.
    Niegisch, G.
    Albers, P.
    Antoch, G.
    Radtke, J. P.
    ABDOMINAL RADIOLOGY, 2024, 49 (01) : 192 - 201
  • [5] MRI characteristics and oncological follow-up of patients with ISUP grade group 4 or 5 prostate cancer
    M. Boschheidgen
    L. Schimmöller
    R. Kastl
    L. R. Drewes
    K. Jannusch
    K. L. Radke
    J. Kirchner
    T. Ullrich
    G. Niegisch
    P. Albers
    G. Antoch
    J. P. Radtke
    Abdominal Radiology, 2024, 49 : 192 - 201
  • [6] Immunogenomic landscape of grade group 5 prostate cancer predicts risk of lethal outcomes and may inform treatment response
    Yamoah, Kosj
    Awasthi, Shivanshu
    Mahal, Brandon
    Zhao, Shuang G.
    Abraham-Miranda, Julieta
    Gerke, Travis A.
    Davicioni, Elai
    Rounbehler, Robert J.
    Berglund, Anders E.
    Grass, Daniel G.
    Park, Jong Y.
    Pow-Sang, Julio M.
    Fernandez, Daniel
    Jain, Rohit K.
    Schaeffer, Edward M.
    Freedland, Stephen
    Spratt, Daniel E.
    Den, Robert B.
    Kohli, Manish
    Rebbeck, Timothy R.
    Fang, Felix Y.
    CANCER RESEARCH, 2020, 80 (16)
  • [7] Clinical Outcomes among Patients with Radiorecurrent Gleason Grade Group 5 Prostate Cancer: Impact of Initial Treatment Strategy
    Levin-Epstein, R.
    Cook, K.
    Chu, F. I.
    Ciezki, J. P.
    Stock, R. G.
    Merrick, G. S.
    Demanes, D. J. J.
    Spratt, D. E.
    Abu-Isa, E. I.
    Pomerantz, M.
    Tran, P. T.
    Nguyen, P. L.
    Wedde, T.
    Lilleby, W.
    Krauss, D. J.
    Alam, R.
    Steinberg, M. L.
    Horwitz, E. M.
    King, C. R.
    Kishan, A. U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E289 - E290
  • [8] Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results
    Shore, Neal
    Kaplan, Steven A.
    Tutrone, Ronald
    Levin, Richard
    Bailen, James
    Hay, Alan
    Kalota, Susan
    Bidair, Mohamed
    Freedman, Sheldon
    Goldberg, Kenneth
    Snoy, Frederick
    Epstein, Jonathan, I
    WORLD JOURNAL OF UROLOGY, 2020, 38 (12) : 3101 - 3111
  • [9] Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results
    Neal Shore
    Steven A. Kaplan
    Ronald Tutrone
    Richard Levin
    James Bailen
    Alan Hay
    Susan Kalota
    Mohamed Bidair
    Sheldon Freedman
    Kenneth Goldberg
    Frederick Snoy
    Jonathan I. Epstein
    World Journal of Urology, 2020, 38 : 3101 - 3111
  • [10] Prostate Cancer Grade Group 4: Gleason 3+5=8 and 5+3=8 Outcomes Versus 4+4=8
    Harding-Jackson, Nicholas
    Whittington, Elizabeth
    Eastwood, Daniel C.
    Tjionas, George A.
    Kryvenko, Oleksandr N.
    Upadhyay, Swikrity
    Jorda, Merce
    Kzkowski, Kenneth A.
    MODERN PATHOLOGY, 2016, 29 : 237A - 237A
123